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2ABSTRACT
Objective
More people are living with the consequences of cancer and comorbidity. We describe frequencies
of comorbidities in a colorectal cancer cohort and associations with health and wellbeing outcomes
up to five years following surgery.
Methods
Prospective cohort study of 872 colorectal cancer patients recruited 2010-2012 from 29 UK centres,
awaiting curative intent surgery. Questionnaires administered at baseline (pre-surgery), 3, 9, 15, 24
months, and annually up to 5 years. Comorbidities (and whether they limit activities) were self-
reported by participants from 3 months. The EORTC QLQ-C30 and QLQ-CR29 assessed global
health/quality of life (QoL), symptoms and functioning. Longitudinal analyses investigated associations
between comorbidities and health and wellbeing outcomes.
Results
At baseline, the mean age of participants was 68 years, with 60% male and 65% colon cancer. 32%
had one and 40% had >2 comorbidities. The most common comorbidities were high blood pressure
(43%), arthritis/rheumatism (32%) and anxiety/depression (18%). Of those with comorbidities, 37%
reported at least one that limited their daily activities. Reporting any limiting comorbidities was
associated with poorer global health/QoL, worse symptoms and poorer functioning on all domains
over 5 years’ follow-up. Controlling for the most common individual comorbidities,
depression/anxiety had the greatest deleterious effect on outcomes.
Conclusions
Clinical assessment should prioritise patient-reported comorbidities and whether these
comorbidities limit daily activities, as important determinants of recovery of QoL, symptoms and
functioning following colorectal cancer. Targeted interventions and support services, including
3multi-professional management and tailored assessment and follow-up, may aid recovery of health
and wellbeing recovery in these individuals.
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BACKGROUND
Colorectal cancer (CRC) is one of the most common cancers worldwide, with an estimated incidence
of over 1.3 million and this is increasing1. Five-year survival rates in the UK stand at 57% and 65% in
the US2,3. CRC is more likely in older adults, with 60% of survivors aged over 65 years4.
Comorbidity is defined as the presence of distinct medical condition(s) in addition to the particular
index disease, in this case CRC5. Multiple comorbidity is progressively more common with age, thus
older CRC survivors generally present with high levels of comorbidity6. CRC survivors also have higher
rates of comorbid disease compared with the general population7, with around 40-50% of CRC
patients reported to have >2 comorbidities8,9.
Living with comorbidity after CRC diagnosis is now the norm rather than the exception. Therefore,
investigation into how comorbidities affect CRC survivors’ health and wellbeing has become
increasingly important. Cancer survivors often report poorer health and wellbeing compared to
healthy populations, and independently, long-term chronic conditions negatively influence QoL10,11.
Whilst there is a growing body of literature exploring the effect of comorbidities in people recovering
from CRC, there is significant variability in study sample sizes12,13, participant characteristics14,15, time
points of assessment9,12, and it is not always possible to identify CRC specific data in cohort studies
that include multiple tumour groups16. In addition, investigations of the impact of comorbidities on
4QoL, symptoms and functioning following a CRC diagnosis is limited by cross-sectional design9,17, a
narrow range of outcomes17,18 and methods used to determine comorbidity status17,19.
Most studies focus on number of comorbidities9,20, or comorbidity severity using weighted scales,
where severity is based on the pre-defined mortality risk of individual conditions, such as the Charlson
Comorbidity Index (CCI)13,19,21 or similar indices22. Few studies describe patient-reported severity,
such as limitations on activities caused by comorbidities. Those that do are either cross-sectional,
limited to self-reported depression, do not exclusively examine the impact of comorbidity limitation
on wellbeing, or present data from mixed tumour groups12,19,23.
Few studies have described associations between comorbidities, and health and wellbeing over time.
Associations with pain, fatigue and mental wellbeing up to 1 year following a CRC diagnosis, and
fatigue and QoL over time in longer term survivors have been described, yet only in relation to the
number of comorbidities18,24. The role of individual comorbid conditions is largely overlooked in
studies.
Only one longitudinal study has mapped comorbidity prevalence up to one year; however, this study
was non-population based and limited to CRC survivors >65 years14. Similarly, no studies describe
the demographic, clinical and treatment characteristics of CRC survivors with comorbidities. Using
results from the ColoREctal Wellbeing study (CREW)25; a longitudinal cohort study investigating
recovery of health and wellbeing in the 5 years following colorectal cancer, this paper aims to
determine:
1) The frequency of comorbidities, their limiting effects on daily activities, and the frequency of
individual comorbid conditions among CRC survivors.
2) The association between comorbidities, and recovery of QoL, symptom and functioning
outcomes.
3) The demographic and clinical factors that characterise comorbid CRC survivors.
5METHODS
Design
CREW is a prospective longitudinal cohort study of patients with non-metastatic CRC undergoing
curative intent surgery. Further details are described elsewhere25.
Participants
Eligible patients had a diagnosis of Dukes’ stage A-C colorectal cancer, were being treated with
curative intent surgery, aged >18 years and able to complete questionnaires. Having a prior cancer
diagnosis was an exclusion criterion.
Procedure
Participants were recruited from 29 UK hospitals between November 2010 and March 2012. Self-
report questionnaires were completed before surgery (baseline) and mailed questionnaires were sent
at regular intervals: 3, 9, 15, 24 months, and annually up to 5 years. Clinical and treatment
characteristics were identified from NHS medical data. Ethical approval was granted by the UK NHS
Health Research Authority NRES Committee South Central - Oxford B (REC ref: 10/H0605/31).
Measures
Full details of the measures used in CREW have been published25. Measures that pertain to the
findings presented in this paper are summarised below.
Socio-demographic, Clinical and Treatment Data
Clinical and treatment data were obtained (with consent) from medical notes: tumour site, Dukes’
stage, nodal involvement, how CRC was detected, family history of CRC, presence of a stoma, neo-
adjuvant and adjuvant treatment. Neighbourhood deprivation was derived from postcodes using the
6Index of Multiple Deprivation26. Domestic and employment status were assessed by participant self-
report in questionnaires.
Comorbidity Data
Patient self-reported comorbidity status remains an accurate method for health research against
clinical record review27. Self-reported comorbidity data were collected at 3, 15, 24, 36, 48 and 60
months. The list relating to 12 individual conditions or disease groups was a study specific measure
(not formally validated) informed by Ramsey et al12, with format informed by the Self-Administered
Comorbidity Questionnaire28. The list (Figure 1) asks whether a doctor has ever told the participant
they have the condition, whether the condition limits typical daily activities and the severity of such
impact (ranked from 1-7 on Likert scale). At 24 months, an additional question asked whether each
condition had been diagnosed before or after CRC diagnosis.
**Insert Figure 1**
QoL, Symptoms and Functioning
QoL, symptoms and functioning were assessed using the validated European Organisation for
Research and Treatment of Cancer QoL (EORTC QLQ) core (C30) questionnaire29 and the CRC
component (CR29)30, from 3 months onwards.
Global health status/QoL scale of the QLQ-C30 was used to represent overall QoL (comprises 2 items).
Analyses of symptoms focussed on those most frequently reported in CRC9,13,31: pain, fatigue (from
QLQ-C30), urinary and bowel symptoms (from QLQ-CR29). Physical, role, cognitive, emotional and
social functioning was assessed using QLQ-C30 subscales.
Statistical Analysis
Subscale scores from the EORTC questionnaires were calculated according to published guidelines29.
To avoid problems with multiple testing of a large number of individual symptoms, summary scores
representing urinary symptoms and bowel symptoms were calculated by taking the mean of QLQ-
7CR29 subscales: (a) urinary frequency, urinary incontinence and dysuria for urinary symptoms, and (b)
blood and mucus in stool, stool frequency, abdominal pain, pain in buttocks/anal area/rectum,
bloating, flatulence and faecal incontinence for bowel symptoms.
Due to initial analyses indicating the stability in prevalence and chronicity of comorbidities over follow-
up, statistical analyses used 3 month comorbidity data.
In the first part of the analyses, associations between the number of comorbidities reported at 3
months and baseline socio-demographic, clinical and treatment factors, were assessed using the chi-
square test or chi-square test for trend, where appropriate. The Index of Multiple Deprivation was
categorised into quintiles26. Performance status was not captured.
For the second part, longitudinal analyses were conducted using generalised estimating equations,
based on all available completed questionnaires up to 60 months. Analyses assessed the associations
between EORTC subscale scores as dependent variables and comorbidities reported at 3 months (five
most prevalent comorbid conditions, and the comorbidity status itself categorised as none, non-
limiting or limiting) as independent variables at the 5% significance level. Separate models were fitted
for each EORTC subscale of global health status/QoL, symptoms and functioning.
The first set of multivariable regression models included independent variables separately in each
model and were adjusted for time since surgery and those demographic, clinical or treatment factors
significantly associated with total numbers of comorbidities in the first analyses.
The second set of multivariable regression models focused on examining multiple effects of the
significant comorbidity predictors. Independent (comorbidity) variables statistically significant in the
first set of regression models were put together in the second set, again adjusting for time since
surgery and demographic/clinical/treatment factors identified as significant in initial analyses.
8Participants with missing questionnaires were included in analyses for time-points for which they
provided data; there was no imputation of missing questionnaires, or socio-demographic, clinical,
treatment or comorbidity data. Missing data on the EORTC measures were dealt with using published
guidelines29 30.
Longitudinal analyses involving individual comorbidities encompassed the five most prevalent
individual conditions (small numbers restricted detailed analysis for less prevalent comorbidities and
any associations of individual conditions that limited daily activities).
In line with published guidance, clinically meaningful differences were determined by a >10 point
difference in EORTC subscale scores32.
RESULTS
Participants
1,350 eligible individuals were identified. Of those eligible, 78% (n=1,055) agreed to participate; of
whom 86% (n=909) gave full consent to participate and 14% (n=146) gave permission for only clinical
data to be collected. 37 were found to be ineligible following surgery. Excluding 11 individuals who
withdrew or died between consent and baseline, 861 participants consented to follow-up. This sample
is representative of eligible patients treated during the recruitment period. Response rates were 88%
at baseline and 69% at 60 months. Comorbidity data were available for 99% of those responding
(n=659) at 3 months and 87% (n=324) at 60 months.
Mean age at baseline was 68 years (range 27 to 95 years). The majority were of white ethnic origin
and 60% were male. Most participants were retired (60%), and over 60% were married or living with
a partner. Most participants had colon cancer (65%), 35% rectal tumours. Over 53% had Dukes’ stage
B, 20% had stage C1, and 12-14% had stage A or C2 (1% was undetermined) 18% received neo-
adjuvant treatment and 46% adjuvant chemotherapy or radiotherapy.
Frequency and Impact of Comorbidities
9At 3 months, 28% reported no comorbidities, 32% reported one, 23% two and 17% three or more. Of
the 72% (n=476) with comorbidities, the median number was two. Of those with comorbidities, 37%
reported at least one that limited their daily activities, with 13% reporting two or more limiting
comorbidities (Table 1). The proportion of limiting comorbidities remained consistent over time.
Most participants (62% at 3 months) reported that their comorbidities limited daily activities
“moderately”, which remained fairly consistent over follow-up (Appendix 1).
Individual Comorbidities
The most common individual comorbidities reported at 3 months were high blood pressure (43%),
arthritis/rheumatism (arthritis) (32%), depression/anxiety (18%), diabetes/high blood sugar (diabetes)
(16%) and asthma/chronic lung disease (lung disease) (16%). There was less than a 7% change in the
prevalence of all conditions over follow-up (Appendix 2).
Results suggest that the majority of comorbid conditions were diagnosed prior to CRC diagnosis
(participants responded to this question at 24 months). The exceptions to this were stroke/brain
haemorrhage and liver disease/cirrhosis, of which 50% and 80% (respectively) were diagnosed
following CRC diagnosis. Of note is the relatively high percentage (46%) of comorbid
depression/anxiety diagnosed post CRC diagnosis, although numbers were small for analysis. All other
conditions (apart from inflammatory bowel disease) were diagnosed before CRC diagnosis in >78% of
individuals.
Arthritis and heart failure were reported to be the most limiting conditions. Of participants reporting
these conditions, >50% stated it limited their daily activities. Stroke/brain haemorrhage, myocardial
infarction and angina were reported as limiting by >40% of respondents with each condition, and >35%
of participants with depression/anxiety and lung disease reported them as limiting. High blood
pressure was the most prevalent, but least limiting condition. Of participants with diabetes, 14%
reported the condition as limiting (Appendix 2).
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Demographic and Clinical Characteristics
Socio-demographic, clinical and treatment characteristics of CRC patients, and their associations with
total number of comorbidities are presented in Appendix 3. Ethnicity is not presented as numbers in
minority groups were too small for analysis. Comorbidities were significantly more common in older,
retired or unemployed respondents. No significant associations were found between total number of
comorbidities and any other socio-demographic, clinical or treatment factors, nor for number of
comorbidities that limited daily activities.
Comorbidities and QoL, Symptom and Functioning Outcomes
Due to high correlation between age and employment status, only age at baseline was included in the
multivariable regression analyses.
The first set of longitudinal multivariable regression models adjusted for age and time since surgery
(from baseline to 60 months), illustrates that the presence of any limiting comorbidities was
significantly associated with poorer global health status/QoL, symptom and functioning outcomes
across all domains (p<0.001), including: increased fatigue, pain, urinary and bowel symptoms, and
reduced physical, role, emotional, cognitive and social functioning (Appendix 4). Findings illustrated
clinically meaningful differences associated with the presence of limiting comorbidities across all
outcomes (except for urinary and bowel symptoms). In contrast, the presence of non-limiting
comorbidities was only significantly associated with increased pain and worse physical functioning
(p<0.05).
Of the five most prevalent individual comorbid conditions reported at 3 months, arthritis and
depression/anxiety were significantly associated with poorer global health status/QoL, symptom and
functioning outcomes across all domains (p<0.001). Depression/anxiety appeared to have the
greatest association with poorer outcomes, with clinically meaningful differences across all outcomes
(except for urinary and bowel symptoms). Lung disease was also significantly associated with poorer
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outcomes, with the exception of urinary symptoms. Diabetes and high blood pressure were
significantly associated with increased pain and poorer physical functioning, with diabetes also
associated with worse urinary symptoms (Appendix 4).
Once adjusted for all significant comorbidity predictors, final multivariable regression models
confirmed that the presence of any limiting comorbidities remained a statistically strong and
significant predictor of all health and wellbeing outcomes (p<0.001), with the exception of emotional
functioning (Table 2). The biggest and clinically significant differences were observed for pain, fatigue,
physical, role, social and cognitive functioning.
The presence of depression/anxiety remained a statistically significant and strong predictor of poorer
outcomes across all domains, with the exception of urinary symptoms. Clinically meaningful
differences were observed for global health status/QoL, fatigue, emotional and social functioning.
Arthritis, diabetes and high blood pressure did not remain significantly associated with any outcomes.
Lung disease remained statistically significant only in association with poorer global health status/QoL
and physical functioning (p<0.05).
For participants reporting both limiting comorbidities and depression/anxiety, differences in outcome
scores were approximately doubled for domains including fatigue, pain, physical, role and social
functioning, with highly clinically significant differences in outcome scores of >20.
DISCUSSION
This is the first paper to describe the stability of comorbidity prevalence, individual comorbidities and
patient-reported limitations of comorbidities, and demonstrate their significant associations with
poorer QoL, symptoms and functioning up to 5 years following CRC diagnosis. We demonstrate that
it is not the presence of comorbidities per se, but the limitations on daily activities imposed by
comorbidities, which has the greatest impact on health and wellbeing.
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Frequency and prevalence of comorbidity
Our results demonstrate that 27% of CRC survivors (37% of those with comorbidities), report at least
one comorbidity that limits their daily activities. Ramsey et al, the only other study to investigate self-
reported comorbidity limitation, found similar findings, with 32% reporting currently limiting
comorbidities, although their findings relate to longer-term (> 5 years) CRC survivors12. Our results
also add to growing evidence that 70-80% of CRC survivors are living with at least one comorbidity9,12,18.
Anxiety and depression are increasingly recognised as common following CRC17, yet CREW adds to
only a handful of studies to include them in its assessment of comorbidity8,18. Approximately half of
individuals stated their depression/anxiety was not pre-existing, but was diagnosed after CRC. Despite
low response rates for this question (50%), high rates of depression post-cancer diagnosis, particularly
in CRC, have been demonstrated elsewhere33. The stability in prevalence of depression/anxiety in the
5 year follow-up reported here, suggests that often, diagnoses may occur within 3 months of a CRC
diagnosis. Our findings highlight the importance of screening for mental wellbeing and offering
appropriate support. This is emphasised by research detailing how significantly fewer CRC survivors
actively seek help for psychological problems than for physical concerns34.
The frequency of hypertension, arthritis, diabetes and lung disease are comparable to other studies7,18,
and reflect their prevalence in the general population35. Results demonstrating a <10% prevalence of
angina, myocardial infarction and heart failure in the CREW cohort, are at odds with higher prevalence
in other CRC studies, and in the general population8,34. This likely reflects differences in the criteria
for assessing conditions, for example as collective ‘heart disease’ or here, as separate conditions.
Association of comorbidities with QoL, functioning and symptom outcomes
Our data confirm the importance of understanding whether comorbidities are disrupting daily
activities, as these can have a greater, negative impact on health and wellbeing during recovery from
CRC. Even after accounting for all significant comorbidity predictors, patient-reported limitations of
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comorbidities prevailed as a strong and significant predictor across all QoL, functioning and symptom
outcomes. The only exception to this was emotional functioning, where the presence of
depression/anxiety held prominent significance. Astrup et al also described associations between
limitations of comorbidities and reduced QoL and greater symptom experience, although their study
was not limited to CRC23. The only other study to describe similar associations with QoL in CRC patients,
combined patient reported and pre-defined severity scores, meaning that results do not solely reflect
patient reports of limitation12. Studies using clinically derived assessments (pre-defined weighted
scales) of comorbidity severity, have been inconsistent in demonstrating a link between greater
severity and poorer QoL19,22. Weighted severity scores were designed to predict survival outcomes
and therefore do not capture the complexity and impact of living with comorbidities21. Research
demonstrating associations between performance status of cancer patients and QoL outcomes,
supports limitation of daily activities as an important influencer of health and wellbeing16. Our findings
demonstrate that self-reported limitations of comorbidities have an important and much greater
influence on health and wellbeing outcomes, compared to comorbidity presence alone. Whilst the
presence and clinically defined severity of comorbidities are important, future assessment should
include appraisal of how much they disrupt people’s lives.
Perhaps unsurprisingly, the strongest effects of having a limiting comorbidity were seen with pain,
physical and role functioning outcomes. Identified associations with pain are supported elsewhere36,37.
However, we describe for the first time the persistent association between limiting comorbidities and
symptom outcomes up to 5 years post CRC, in particular the association between comorbidities and
poorer urinary and bowel symptoms. Similar associations have been described in rectal cancer38, but
this is a new finding in CRC. These findings hold significance, as multiple studies report urinary and
bowel symptoms as predominant, persistent and burdensome following CRC treatment9,31.
Previous cross-sectional studies have demonstrated links between depression/anxiety and poorer QoL,
fatigue, pain, physical and emotional functioning in CRC survivors17,19. Our findings support and
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expand on this previous literature by demonstrating that depression/anxiety is the most significant
individual predictor of poorer health and wellbeing outcomes (with the exception of urinary symptoms)
in CRC survivors for up to 5 years, even after adjusting for the presence of any limiting comorbidities
and other individual conditions. Moreover, our findings suggest a double health and well-being
burden of having both depression/anxiety and any limiting comorbidities.
Interestingly, significant associations of arthritis, as the most limiting comorbidity, disappeared for all
outcomes after the inclusion of the presence of any limiting comorbidities in the final models, which
likely accounted for the health importance of arthritis. This finding suggests that arthritis, by its
limiting nature, is associated with prolonged and poor health and wellbeing outcomes, supporting its
associations with greater pain and poorer physical functioning seen elsewhere8.
Study Limitations
Previous cancer studies have demonstrated that participants are less likely to have severe
comorbidities than non-responders22. This should be taken into consideration when interpreting
results, as it is possible that our findings may under-represent the true extent and impact of
comorbidities. Assessment of EORTC QLQ-C30, QLQ-CR29 and comorbidities was not included within
questionnaires until 3 months due to burden of data collection close to diagnosis. Participants were
asked whether comorbidities were diagnosed prior to their CRC diagnosis at 24 months, as such,
responses are liable to recall bias. The list of comorbidities available for self-report was limited to 12
individual conditions or disease groups and did not encompass all potential comorbid conditions (for
example, obesity). A prior diagnosis of cancer was an exclusion criterion, meaning that previous
cancer diagnoses could not be included in comorbidity assessment. Falling response rates over follow-
up mean that apparent trends in comorbidities over time need to be interpreted with caution. Any
apparent decline in absolute numbers of individuals reporting comorbidities could be due to more
unwell individuals withdrawing from the study.
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Conclusions and Clinical Implications
Our findings highlight the importance of identifying patient-reported presence and limitations of
comorbidities, as important health and wellbeing predictors both during and beyond CRC treatment.
The stability in prevalence and severity of comorbidity, suggests that CRC patients at risk of poorer
outcomes up to 5 years following a diagnosis, can be identified early, and appropriate support put in
place. As such, key consideration should be given to optimising comorbidity management before CRC
treatment and clinical follow-up that incorporates comorbidity assessment, is individualised, and
takes place as soon as possible following a CRC diagnosis.
The International Society of Geriatric Oncology (SIOG) recommends geriatrician involvement in the
management of cancer patients with comorbidities, and treatment decisions that consider
comorbidities39. We propose that targeted interventions and support services, including multi-
professional management and tailored assessment and follow-up, may aid recovery of health and
wellbeing.
CREW highlights the importance of including conditions such as musculoskeletal and mood disorders,
and patient-reported limitations, in future clinical and research assessments of comorbidity. The
inclusion of self-reported health status in the assessment of comorbid CRC patients, is a
recommendation echoed by NICE multimorbidity guidance40 and could help to identify CRC patients
at risk of reduced health and wellbeing.
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Table 1. Number of comorbidities and number of limiting comorbidities for the CREW cohort
(reported at 3 months following primary CRC surgery)
Number of comorbidities 3 months
n=659
Number of limiting comorbidities 3 months
n=476
0 183
(27.7%)
0 249 (52.3%)
1 211
(32.0%)
1 115 (24.2%)
2 150
(22.8%)
>2 62 (13.0%)
>3 115
(17.4%)
Missing data 50 (10.5%)
Presence of any comorbidities 476
(72.2%)
Presence of any limiting comorbidities 177 (37.2%)
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Table 2. Mean differences in EORTC subscale scores over follow-up between 3 and 60 months following surgery, estimated from multivariable regression
models adjusted for age at baseline, time since surgery, comorbidity status and five most prevalent conditions
Independent Variables
Dependent Variables: EORTC subscale scores 1
Global
health
status /
QoL2
Fatigue3 Pain3 Urinarysymptoms3,4
Bowel
symptoms3,5
Physical
functioning2
Role
functioning2
Emotional
functioning2
Cognitive
functioning2
Social
functioning2
Model 1 Model 2 Model 3 Model 4 Model 5 Model 6 Model 7 Model 8 Model 9 Model 10
1) Comorbidity status:
- None (ref) 0 0 0 0 0 0 0 0 0 0
- Yes, non-limiting comorbidities 0.4 0.4 2.8 0.6 1.4 -1.7 0.2 1.3 -0.7 0.6
- Yes, limiting comorbidities -8.3*** 13.6*** 19.1*** 6.3*** 6.4*** -16.3*** -15.0*** -5.1 -10.2*** -11.3***
2) High blood pressure
- No (ref) 0 0
- Yes -1.0 0.01
3) Arthritis/rheumatism
- No (ref) 0 0 0 0 0 0 0 0 0 0
- Yes -3.2 3.3 4.8 0.9 0.9 -0.9 -3.2 -0.9 0.5 -3.6
4) Depression/anxiety
- No (ref) 0 0 0 0 0 0 0 0 0 0
- Yes -10.0*** 12.6*** 6.7* 3.2 4.2* -8.7** -9.1** -18.8*** -9.6** -10.4***
5) Diabetes/high blood sugar
- No (ref) 0 0 0
- Yes 1.6 2.7 -2.2
6) Asthma/chronic lung disease
- No (ref) 0 0 0 0 0 0 0 0 0
- Yes -5.2* 3.0 -0.3 -0.3 -5.0* -4.5 -1.8 -1.8 0.2
7) age at baseline -0.1 0.01 -0.2 0.1* -0.3*** -0.4*** -0.1 0.2* 0.1 0.1
8) time since surgery 0.1*** -0.2*** -0.1** 0.02 -0.1*** 0.1** 0.2*** 0.1*** 0.2*** 0.3***
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Notes: *** p<0.001; ** p<0.01; * p<0.05; Grey areas indicate that the referred independent variable was not included in the final multivariable model of the referred outcome,
because it was statistically insignificant in the original model adjusted only for age and time since surgery (see Appendix 4).
1 EORTC subscale from QLQ-C30 or CR-29
2 Higher scores for global health status/QoL and functioning subscales indicate better health/QoL and functioning
3 Higher scores for symptom subscales indicate worse symptoms
4 Urinary symptoms include urinary frequency, urinary incontinence and dysuria
5 Bowel symptoms include blood and mucus in stool, stool frequency, abdominal pain, pain in buttocks/anal area/rectum, bloating, flatulence and faecal incontinence
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Figure title/legends
Figure 1. Self-report comorbidities section of CREW questionnaires
Appendix 1. Number and severity of limiting comorbidities reported at 3, 15, 24, 36, 48 and 60
months following primary colorectal cancer surgery
How severely has the condition limited your activities
n(%)
Total number of
limiting
comorbidities
1-2
Mild
3-5
Moderate
6-7
Severe
Missing data
3 Months 69 (25%) 170 (62%) 27 (10%) 7 (3%) N = 273
15 Months 64 (31%) 104 (50%) 26 (12%) 15 (7%) N = 209
24 Months 65 (34%) 101 (52%) 22 (11%) 5 (3%) N = 193
36 Months 51 (31.7%) 87 (54.0%) 18 (11.2%) 5 (3.1%) N = 161
48 Months 51 (27.6%) 104 (56.2%) 25 (13.5%) 5 (2.7%) N = 185
60 Months 34 (22.1%) 94 (61.0%) 20 (13.0%) 6 (3.9%) N = 154
Appendix 2. Prevalence of individual self-reported comorbidities at 3, 15, 24, 36, 48 and 60 months
following primary colorectal cancer surgery, and prevalence of those reported to limit daily activities
at 3 months
Self-reported
comorbidity
Prevalence of Comorbidity
(n= answered question)
3 Months 15Months
24
Months
36
Months
48
Months
60
Months
Prevalence
at 3
months
Prevalence
of those
with
comorbidity
that report
it limits
daily
activities
Prevalence
at 15
months
Prevalence
at 24
months
Prevalence
at 36
months
Prevalence
at 48
months
Prevalence
at 60
months
High blood
pressure
259
(43.2%) 15 (5.8%)
214
(41.2%)
184
(38.5%)
140
(38.1%)
141
(39.8%)
134
(43.8%)
N = 600 N = 519 N = 478 N = 367 N = 354 N = 306
Arthritis or
rheumatism
186
(32.0%) 99 (53.2%)
174
(34.2%)
155
(32.6%)
133
(36.9%)
126
(36.6%)
105
(34.3%)
N = 581 N = 509 N = 476 N = 360 N = 344 N = 306
Depression or
anxiety
100
(18.2%) 36 (36.0%)
71
(14.4%)
66
(14.0%)
46
(13.3%)
51
(15.4%)
40
(13.7%)
N = 550 N = 494 N = 470 N = 345 N = 332 N = 292
Diabetes or
high blood
sugar
89
(16.2%) 12 (13.5%)
82
(16.5%)
74
(15.7%)
65
(19.0%)
59
(18.0%)
66
(23.1%)
N = 547 N = 496 N = 472 N = 342 N = 328 N = 286
Asthma,
chronic lung
disease,
bronchitis or
emphysema
85
(15.7%)
30 (35.3%)
70
(14.3%)
66
(13.9%)
49
(14.2%)
49
(14.6%)
48
(16.4%)
N = 542 N = 491 N = 475 N = 345 N = 335 N = 292
Chest pain or
angina
55
(10.2%) 22 (40.0%)
40 (8.1%) 43 (9.1%) 28 (8.3%) 23 (6.9%) 24 (8.2%)
N = 540 N = 492 N = 473 N = 339 N = 333 N = 293
Inflammatory
bowel disease,
colitis or
Crohn’s disease
46 (8.7%)
16 (34.8%)
31 (6.4%) 27 (5.8%) 17 (5.0%) 15 (4.6%) 15 (5.2%)
N = 527 N = 482 N = 468 N = 340 N = 329 N = 288
Heart attack or
myocardial
infarction
40 (7.5%)
16 (40%)
40 (8.2%) 36 (7.7%) 22 (6.6%) 22 (6.6%) 20 (6.8%)
N = 533 N = 490 N = 469 N = 332 N = 333 N = 293
Stroke or brain
haemorrhage
21 (4.0%)
9 (42.9%)
11 (2.3%) 10 (2.2%) 8 (2.4%) 11 (3.3%) 11 (3.8%)
N =529 N = 485 N = 465 N = 335 N = 330 N = 289
Heart failure
21 (4.0%)
11 (52.4%)
25 (5.1%) 21 (4.5%) 21 (6.1%) 18 (5.4%) 13 (4.5%)
N = 527 N = 487 N = 468 N = 342 N = 335 N = 290
Liver disease or
cirrhosis
8 (1.5%)
1 (12.5%)
13 (2.7%) 11 (2.3%) 11 (3.3%) 7 (2.1%) 5 (1.7%)
N = 525 N = 485 N = 469) N = 338 N = 327 N = 289
Bleeding from
stomach ulcers
3 (0.6%)
0 (0.0%)
2 (0.4%) 4 (0.9%) 0 (0.0%) 5 (1.5%) 3 (1.0%)
N = 523 N = 487 N = 469 N = 338 N = 329 N = 287
Appendix 3. Number of comorbidities reported at 3 months following colorectal cancer surgery
according to socio-demographic, clinical and treatment characteristics
Number of Comorbidities (at 3M) Presence of
comorbidities
(>1)
Chi Square
test comparing
presence
versus absence
of
comorbidities:
p-value
0 1 2 3+ Tota
l
Socio-dem
ographic
Factors
Age group (years) < 0.001t
<50 25
(58%)
10
(23%)
5
(12%)
3 (7%) 43 18 (42%)
51-60 32
(35%)
31
(34%)
22
(24%)
7 (8%) 92 60 (65%)
61-70 59
(27%)
75
(35%)
48
(22%)
35
(16%)
217 158 (72.8%)
71-80 28
(18%)
45
(29%)
43
(28%)
38
(25%)
154 126 (81.8%)
>80 8
(16%)
18
(35%)
15
(29%)
10
(20%)
51 43 (84.3%)
Gender 0.458
Male 113
(29%)
133
(34%)
87
(22%)
63
(16%)
396 283 (71.5%)
Female 70
(27%)
78
(30%)
63
(24%)
52
(20%)
263 193 (73.4%)
Deprivation Index
(quintiles)
0.206t
1st (least deprived) 42
(31%)
44
(32%)
32
(23%)
19
(14%)
137 95 (69.3%)
2nd 37
(26%)
46
(33%)
35
(25%)
23
(16%)
141 104 (73.8%)
3rd 33
(27%)
37
(30%)
30
(25%)
22
(18%)
122 89 (73.0%)
4th 33
(28%)
49
(41%)
22
(18%)
16
(13%)
120 87 (72.5%)
5th (most deprived) 32
(25%)
32
(25%)
30
(23%)
34
(27%)
128 96 (75.0%)
Domestic Status 0.314
Married/Living
with partner
128
(29%)
145
(32%)
106
(24%)
68
(15%)
447 319 (71.4%)
Single/Widowed/
Divorced/
Separated
42
(25%)
51
(30%)
39
(23%)
36
(21%)
168 126 (75.0%)
Employment Status < 0.001
Employed
(Employed FT, PT,
on unpaid or sick
leave)
76
(43%)
60
(34%)
31
(18%)
9 (5%) 176 100 (56.8%)
Unemployed
(Unemployed or
disabled does not
work)
4 (2%) 12
(41%)
7
(24%)
6
(21%)
29 25 (86.2%)
Retired 89
(22%)
124
(31%)
106
(26%)
88
(22%)
407 318 (78.1%)
C
li
nic Tumour site 0.133
Colon 109
(25%)
138
(32%)
107
(25%)
77
(18%)
431 322 (74.7%)
Rectum 74
(33%)
73
(32%)
42
(19%)
38
(17%)
227 153 (67.4%)
Dukes’ stage 0.307t
Stage A 30
(29.4%
)
25
(24.5%
)
29
(28.4%
)
18
(17.6%
)
102 72 (70.6%)
Stage B 97
(28%)
117
(34%)
66
(19%)
65
(19%)
345 248 (71.9%)
Stage C1 31
(24%)
41
(31%)
38
(29%)
21
(16%)
131 100 (76.3%)
Stage C2 22
(31%)
23
(33%)
16
(23%)
9
(13%)
70 48 (68.6%)
Nodal Involvement 0.594t
N0 120
(28%)
134
(32%)
88
(21%)
81
(19%)
423 303 (71.6%)
N1 29
(23%)
41
(33%)
34
(27%)
20
(16%)
124 95 (76.6%)
N2 23
(31%)
25
(34%)
16
(22%)
10
(14 %)
74 51 (68.9%)
How cancer was
detected
0.671
Screening 39
(25%)
55
(36%)
36
(23%)
25
(16%)
155 116 (74.8%)
Symptomatic 130
(29%)
139
(31%)
104
(23%)
83
(18%)
456 326 (71.5%)
Emergency
surgery/other
12
(40%)
8
(27%)
5
(17%)
5
(17%)
30 18 (60.0%)
Family History (of
CRC)
0.235
Yes 31
(40%)
25
(32%)
13
(17%)
9
(12%)
78 47 (60.3%)
No 93
(28%)
111
(34%)
73
(22%)
50
(15%)
327 234 (71.6%)
Treatm
entFactors
Presence of a
stoma
0.665
Yes 69
(30%)
73
(32%)
46
(20%)
39
(17%)
227 158 (69.6%)
No 113
(27%)
136
(32%)
101
(24%)
74
(18%)
424 311 (73.3%)
Neo-adjuvant
treatment
0.148
Yes 37
(31%)
43
(36%)
19
(16%)
20
(17%)
119 82 (68.9%)
No 146
(27%)
168
(31%)
128
(24%)
94
(18%)
536 311 (73.3%)
Adjuvant treatment 0.538
Yes 76
(32%)
71
(30%)
59
(25%)
32
(13%)
238 162 (68.1%)
No 107
(26%)
140
(33%)
90
(21%)
83
(20%)
420 313 (74.5%)
t Chi² test for trend used for age group, deprivation index, Dukes’ stage, nodal involvement
Appendix 4. Mean differences in EORTC subscale scores over follow-up between 3 and 60 months following surgery, estimated from multivariable
regression models adjusted for age at baseline and time since surgery
Independent Variables
Dependent Variables: EORTC subscales 1
Global
health
status /
QoL2
Fatigue3 Pain3 Urinarysymptoms3,4
Bowel
symptoms3,5
Physical
functioning2
Role
functioning2
Emotional
functioning2
Cognitive
functioning2
Social
functioning2
1) Comorbidity status (ref: none):
- Yes, non-limiting comorbidities -2.0 2.8 3.7* 1.8 1.2 -3.7* -1.8 -1.0 -1.7 -1.2
- Yes, limiting comorbidities -14.0*** 19.1*** 24.3*** 7.2*** 7.4*** -20.9*** -20.2*** -10.7*** -11.8*** -16.1***
2) High blood pressure (ref: no) -3.1+ 2.3 4.0** 0.6 -1.1+ -4.0** -2.9+ 0.1 0.6 -1.6
3) Arthritis/rheumatism (ref: no) -8.6*** 10.9*** 17*** 4.2*** 4.9*** -12.4*** -13.2*** -6.8*** -5.6*** -11.6***
4) Depression/anxiety (ref: no) -13.7*** 17.6*** 15.9*** 5.8*** 6.7*** -16.8*** -15.6*** -22*** -13.9*** -16.1***
5) Diabetes/high blood sugar (ref: no) -3.6+ 3.6 5.0* 3.9*** -0.2 -6.1** -2.5 1.8 1.2 1.4
6) Asthma/chromic lung disease (ref: no) -7.3** 8.7** 7.0** 1.8 2.8* -11.9*** -9.3*** -4.8* -5.9** -5.4**
*** p<0.001; ** p<0.01; * p<0.05
+ was statistically significant (p<0.05) in a bivariate model and multivariable model adjusted only for time since surgery, but became insignificant after adjusting for age.
1 EORTC subscale from QLQ-C30 or CR-29
2 Higher scores for global health status/QoL and functioning subscales indicate better health/QoL and functioning
3 Higher scores for symptom subscales indicate worse symptoms
4 Urinary symptoms include urinary frequency, urinary incontinence and dysuria
5 Bowel symptoms include blood and mucus in stool, stool frequency, abdominal pain, pain in buttocks/anal area/rectum, bloating, flatulence and faecal incontinence
Figure 1. Self-report comorbidities section of CREW questionnaires
